Chemotherapy News and Research

Latest Chemotherapy News and Research

Duke researchers identify promising target for renal cell carcinomas

All cells need nutrients, but cancer cells are notoriously power hungry. As a result, cancer cells must alter their metabolism to provide the additional fuel needed for them to survive, grow and spread.

4 Feb 2016

NICE recommends Xofigo (radium-223 dichloride) for prostate cancer patients after treatment with docetaxel

The National Institute for Health and Care Excellence has issued its final guidance recommending Xofigo for use on the NHS in England and Wales as an option for treating adult men, with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases, who have received previous docetaxel therapy.

4 Feb 2016

Researchers identify definitive genetic defect in angiocentric gliomas

Diagnosis and treatment decisions for a recently recognized type of children's brain tumor should be improved by the discovery of the genetic mechanism that causes it, say researchers who identified the unusual DNA abnormality in angiocentric gliomas.

2 Feb 2016

Proton beam therapy safe for treating childhood brain cancer medulloblastoma

Proton beam therapy--a more precise form of radiotherapy--to treat the childhood brain cancer medulloblastoma appears to be as safe as conventional radiotherapy with similar survival rates, according to new research published in The Lancet Oncology journal today.

1 Feb 2016

Study provides vital information about mechanisms governing DNA repair

DNA damage can lead to gene inactivation or deregulation and cause various diseases such as cancer; however, many DNA repair mechanisms allow cells to survive against such damage. A study lead by Antoine Simoneau of the laboratory of Dr. Hugo Wurtele, a researcher in immunology-oncology at the Maisonneuve-Rosemont Hospital (CIUSS de l'Est-de-l'Île-de-Montréal) and professor at the Faculty of Medicine, University of Montreal, and recently published in the prestigious journal Nucleic Acids Research, provides valuable information about certain mechanisms governing DNA repair.

31 Jan 2016

COG presents plan to effectively handle future pediatric cancer drug shortages

The Children's Oncology Group has taken steps to help pediatric oncologists across the United States plan for the next shortage of life-saving chemotherapy drugs used for children with cancer. The COG is the world's largest organization devoted exclusively to childhood and adolescent cancer research and is supported in part by the St. Baldrick's Foundation, the largest private funder of childhood cancer research grants.

31 Jan 2016

Young African Americans, Hispanics fare worse when faced with Hodgkin lymphoma

African American and Hispanic adolescents and young adults fare far worse than their white counterparts when faced with a mostly curable type of cancer, Hodgkin lymphoma, a study by a UC Davis epidemiologist has found.

30 Jan 2016

Proton radiotherapy as effective as standard photon therapy in treating pediatric brain tumor

The use of proton radiotherapy to treat the most common malignant brain tumor in children is as effective as standard photon (x-ray) radiation therapy while causing fewer long-term side effects such as hearing loss and cognitive disorders, according to a study receiving online publication in Lancet Oncology.

30 Jan 2016

Sphingosine kinase inhibitor slows castration-resistant prostate cancer cell growth

A first-in-class sphingosine kinase 2 inhibitor slowed the growth of castration-resistant prostate cancer cells, in part by inhibiting the enzyme dihydroceramide desaturase (DEGS), but did not kill them, according to the results of preclinical in vitro and in vivo studies published in the December 2015 issue of Molecular Cancer Therapeutics by researchers at the Medical University of South Carolina and others.

30 Jan 2016

Overall EU cancer, leukaemia mortality rates to fall in 2016

Total cancer-related mortality rates for men and women in the European Union will decline in 2016, say researchers who predict falls in death rates from most neoplasms, including leukaemia.

29 Jan 2016

Eisai's Halaven receives FDA approval for treatment of patients with metastatic liposarcoma

Eisai Inc. announced today that the U.S. Food and Drug Administration approved Halaven (eribulin mesylate) Injection (0.5 mg per mL) for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.

29 Jan 2016

Researchers find how microtubules, motor proteins assemble into macroscopic networks

What bones are to bodies, the cytoskeleton is to cells. The cytoskeleton maintains cellular structure, builds appendages like flagella and, together with motor proteins, powers cellular movement, transport, and division. Microtubules are a critical component of the cytoskeleton, vital for cell division and, because of that, an excellent target for chemotherapy drugs.

29 Jan 2016

Halaven (eribulin mesylate) approved for treatment of liposarcoma

The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be removed by surgery (unresectable) or is advanced (metastatic). This treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug.

28 Jan 2016

Study leads to FDA approval of first immunotherapy for treatment of neuroblastoma

Building upon more than two decades of basic research conducted at Children's Hospital Los Angeles, Araz Marachelian, MD, of CHLA, and her colleagues at pediatric academic centers across the U. S., have shown that an immunotherapy that until now has only been available to patients enrolled in research studies, is equivalent to the product that has been manufactured for commercial use and can be made available to all patients.

28 Jan 2016

Nutrition and breast cancer; starving triple negative breast cancer cells to death: an interview with Associate Professor Jeff Holst

While there are a range of reports that different foods and food groups can increase or decrease your risk of cancer, these associations are very difficult to scientifically verify.

27 Jan 2016

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Astellas US LLC, a United States (U.S.) subsidiary of Tokyo-based Astellas Pharma Inc., and Medivation, Inc. today announced that results from the STRIVE trial of enzalutamide compared to bicalutamide in men with castration-resistant prostate cancer (CRPC) were published in the Journal of Clinical Oncology.

27 Jan 2016

Chemotherapy News and Research

Latest Chemotherapy News and Research

Duke researchers identify promising target for renal cell carcinomas

NICE recommends Xofigo (radium-223 dichloride) for prostate cancer patients after treatment with docetaxel

Researchers identify definitive genetic defect in angiocentric gliomas

Proton beam therapy safe for treating childhood brain cancer medulloblastoma

Study provides vital information about mechanisms governing DNA repair

COG presents plan to effectively handle future pediatric cancer drug shortages

Young African Americans, Hispanics fare worse when faced with Hodgkin lymphoma

Proton radiotherapy as effective as standard photon therapy in treating pediatric brain tumor

Sphingosine kinase inhibitor slows castration-resistant prostate cancer cell growth

Overall EU cancer, leukaemia mortality rates to fall in 2016

Eisai's Halaven receives FDA approval for treatment of patients with metastatic liposarcoma

Researchers find how microtubules, motor proteins assemble into macroscopic networks

Halaven (eribulin mesylate) approved for treatment of liposarcoma

Study leads to FDA approval of first immunotherapy for treatment of neuroblastoma

Nutrition and breast cancer; starving triple negative breast cancer cells to death: an interview with Associate Professor Jeff Holst

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

AVAX announces results of Phase 1/2 OVAX study in patients with advanced ovarian cancer

Palonosetron effective anti-emetic for paediatric chemotherapy patients

Carbapenem-resistant Enterobacteriaceae: an interview with Dr. Michael Dudley

Positive bosutinib response for elderly blast phase CML patient

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in